 Kathryn Colborn
Concepts (435)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 11 | 2025 | 1036 | 2.690 |
Why?
| | Postoperative Complications | 30 | 2025 | 2624 | 2.260 |
Why?
| | Shock, Septic | 5 | 2025 | 221 | 1.360 |
Why?
| | Sepsis | 6 | 2023 | 611 | 1.260 |
Why?
| | Quality Improvement | 14 | 2023 | 1152 | 1.260 |
Why?
| | Urinary Tract Infections | 3 | 2022 | 168 | 1.240 |
Why?
| | Surgical Procedures, Operative | 5 | 2023 | 257 | 1.210 |
Why?
| | Surgical Wound Infection | 7 | 2025 | 302 | 1.200 |
Why?
| | Machine Learning | 8 | 2025 | 487 | 1.190 |
Why?
| | Pancreatic Neoplasms | 10 | 2024 | 931 | 1.170 |
Why?
| | Malaria | 4 | 2023 | 63 | 1.070 |
Why?
| | Retrospective Studies | 47 | 2025 | 15564 | 0.800 |
Why?
| | Postoperative Hemorrhage | 2 | 2023 | 87 | 0.790 |
Why?
| | Models, Statistical | 4 | 2020 | 658 | 0.780 |
Why?
| | Humans | 126 | 2025 | 136783 | 0.760 |
Why?
| | Malaria, Falciparum | 2 | 2018 | 27 | 0.760 |
Why?
| | Databases, Factual | 15 | 2025 | 1347 | 0.750 |
Why?
| | Pain | 2 | 2023 | 755 | 0.680 |
Why?
| | Plasmodium vivax | 2 | 2018 | 4 | 0.680 |
Why?
| | Malaria, Vivax | 2 | 2018 | 4 | 0.680 |
Why?
| | Adenocarcinoma | 5 | 2024 | 936 | 0.650 |
Why?
| | Patient Reported Outcome Measures | 7 | 2024 | 400 | 0.640 |
Why?
| | Artificial Intelligence | 1 | 2023 | 272 | 0.640 |
Why?
| | Surgeons | 4 | 2025 | 296 | 0.610 |
Why?
| | Pneumonia | 3 | 2023 | 638 | 0.610 |
Why?
| | Risk Assessment | 17 | 2024 | 3429 | 0.600 |
Why?
| | Palliative Care | 7 | 2024 | 743 | 0.600 |
Why?
| | Breast Neoplasms | 7 | 2024 | 2239 | 0.600 |
Why?
| | Inpatients | 4 | 2023 | 499 | 0.580 |
Why?
| | Poisson Distribution | 1 | 2018 | 72 | 0.570 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 30 | 0.570 |
Why?
| | Thoracic Surgery | 3 | 2025 | 132 | 0.560 |
Why?
| | Health Plan Implementation | 1 | 2019 | 137 | 0.560 |
Why?
| | Neoadjuvant Therapy | 8 | 2024 | 403 | 0.560 |
Why?
| | Risk Factors | 25 | 2025 | 10331 | 0.520 |
Why?
| | Middle Aged | 40 | 2025 | 33200 | 0.520 |
Why?
| | Mosquito Control | 2 | 2023 | 28 | 0.520 |
Why?
| | Hospitalization | 6 | 2021 | 2195 | 0.510 |
Why?
| | Female | 57 | 2025 | 72840 | 0.490 |
Why?
| | Aged | 32 | 2025 | 23729 | 0.490 |
Why?
| | Mosquito Nets | 1 | 2015 | 2 | 0.480 |
Why?
| | Anopheles | 1 | 2015 | 16 | 0.470 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2023 | 285 | 0.470 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2023 | 292 | 0.460 |
Why?
| | Quality of Life | 10 | 2024 | 2868 | 0.460 |
Why?
| | Male | 50 | 2025 | 67361 | 0.450 |
Why?
| | Drug Prescriptions | 3 | 2021 | 247 | 0.440 |
Why?
| | Adult | 36 | 2025 | 37616 | 0.440 |
Why?
| | Thoracic Surgical Procedures | 2 | 2025 | 73 | 0.410 |
Why?
| | Mastectomy, Segmental | 2 | 2024 | 93 | 0.390 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2023 | 64 | 0.390 |
Why?
| | Patient Discharge | 2 | 2020 | 896 | 0.390 |
Why?
| | Primary Health Care | 3 | 2025 | 1714 | 0.380 |
Why?
| | Hospital Mortality | 1 | 2016 | 900 | 0.380 |
Why?
| | Robotic Surgical Procedures | 2 | 2024 | 126 | 0.370 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 73 | 0.370 |
Why?
| | Preoperative Care | 3 | 2024 | 356 | 0.360 |
Why?
| | Algorithms | 4 | 2019 | 1686 | 0.360 |
Why?
| | Mastectomy | 4 | 2024 | 136 | 0.350 |
Why?
| | Child, Preschool | 15 | 2025 | 11069 | 0.340 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 504 | 0.330 |
Why?
| | Incidence | 8 | 2023 | 2788 | 0.330 |
Why?
| | Influenza, Human | 3 | 2021 | 624 | 0.330 |
Why?
| | Hospitals | 4 | 2025 | 677 | 0.320 |
Why?
| | Emergency Service, Hospital | 4 | 2025 | 2050 | 0.320 |
Why?
| | Emergency Treatment | 2 | 2021 | 117 | 0.320 |
Why?
| | Zebrafish | 2 | 2025 | 495 | 0.320 |
Why?
| | Heart Failure | 5 | 2025 | 2228 | 0.310 |
Why?
| | Colorado | 9 | 2025 | 4491 | 0.310 |
Why?
| | Cohort Studies | 11 | 2024 | 5718 | 0.280 |
Why?
| | Research Design | 3 | 2022 | 1107 | 0.280 |
Why?
| | Osteoarthritis, Knee | 2 | 2021 | 255 | 0.280 |
Why?
| | Aged, 80 and over | 10 | 2024 | 7569 | 0.280 |
Why?
| | Pancreatectomy | 3 | 2024 | 252 | 0.270 |
Why?
| | Cardiac Surgical Procedures | 2 | 2023 | 530 | 0.270 |
Why?
| | Logistic Models | 5 | 2023 | 2060 | 0.270 |
Why?
| | Patient Satisfaction | 4 | 2024 | 650 | 0.270 |
Why?
| | United States | 18 | 2024 | 14660 | 0.270 |
Why?
| | Chagas Disease | 2 | 2018 | 43 | 0.260 |
Why?
| | Seasons | 3 | 2025 | 544 | 0.260 |
Why?
| | Prognosis | 10 | 2024 | 4018 | 0.260 |
Why?
| | Autism Spectrum Disorder | 2 | 2023 | 392 | 0.260 |
Why?
| | Mass Drug Administration | 3 | 2023 | 7 | 0.260 |
Why?
| | Rectal Neoplasms | 2 | 2019 | 149 | 0.260 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2021 | 326 | 0.250 |
Why?
| | Time-to-Treatment | 2 | 2025 | 203 | 0.240 |
Why?
| | Elective Surgical Procedures | 2 | 2024 | 180 | 0.240 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2024 | 390 | 0.240 |
Why?
| | Asthma | 1 | 2019 | 2290 | 0.240 |
Why?
| | Craniofacial Abnormalities | 1 | 2025 | 72 | 0.230 |
Why?
| | CA-19-9 Antigen | 1 | 2024 | 22 | 0.230 |
Why?
| | Treatment Outcome | 13 | 2025 | 10764 | 0.220 |
Why?
| | Varicose Veins | 1 | 2024 | 17 | 0.220 |
Why?
| | Infant | 11 | 2025 | 9442 | 0.220 |
Why?
| | Heart Defects, Congenital | 2 | 2022 | 831 | 0.220 |
Why?
| | Hypothermia | 1 | 2023 | 36 | 0.210 |
Why?
| | Specialties, Surgical | 2 | 2021 | 74 | 0.210 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 35 | 0.210 |
Why?
| | Zebrafish Proteins | 2 | 2025 | 287 | 0.210 |
Why?
| | Metastasectomy | 1 | 2023 | 20 | 0.210 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 49 | 0.200 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 991 | 0.200 |
Why?
| | Predictive Value of Tests | 4 | 2022 | 2030 | 0.200 |
Why?
| | Multivariate Analysis | 2 | 2023 | 1513 | 0.200 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 42 | 0.200 |
Why?
| | Adolescent | 14 | 2025 | 21463 | 0.200 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1294 | 0.200 |
Why?
| | Insecticides | 1 | 2023 | 38 | 0.200 |
Why?
| | MEF2 Transcription Factors | 1 | 2022 | 61 | 0.200 |
Why?
| | Young Adult | 11 | 2020 | 13126 | 0.200 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 66 | 0.200 |
Why?
| | Risk Adjustment | 1 | 2023 | 78 | 0.200 |
Why?
| | Europe | 1 | 2023 | 414 | 0.200 |
Why?
| | Telemetry | 1 | 2022 | 40 | 0.190 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 45 | 0.190 |
Why?
| | Microcephaly | 1 | 2023 | 98 | 0.190 |
Why?
| | Carotid Stenosis | 1 | 2023 | 91 | 0.190 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2023 | 77 | 0.190 |
Why?
| | Medication Therapy Management | 1 | 2023 | 75 | 0.190 |
Why?
| | Polypharmacy | 1 | 2023 | 85 | 0.190 |
Why?
| | Syncope | 1 | 2022 | 52 | 0.190 |
Why?
| | Pneumonectomy | 1 | 2023 | 154 | 0.190 |
Why?
| | Galectins | 1 | 2022 | 24 | 0.190 |
Why?
| | Decision Support Systems, Clinical | 1 | 2025 | 218 | 0.190 |
Why?
| | Information Dissemination | 1 | 2024 | 217 | 0.190 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 43 | 0.190 |
Why?
| | Drug Hypersensitivity | 1 | 2023 | 89 | 0.190 |
Why?
| | Delirium | 1 | 2023 | 86 | 0.180 |
Why?
| | Pain, Postoperative | 2 | 2021 | 267 | 0.180 |
Why?
| | Ivermectin | 1 | 2021 | 13 | 0.180 |
Why?
| | Mozambique | 2 | 2018 | 7 | 0.180 |
Why?
| | Neuroendocrine Tumors | 1 | 2023 | 115 | 0.180 |
Why?
| | Ambulatory Care | 1 | 2025 | 538 | 0.180 |
Why?
| | Vascular Surgical Procedures | 1 | 2024 | 299 | 0.180 |
Why?
| | Communication | 2 | 2025 | 869 | 0.180 |
Why?
| | Program Evaluation | 3 | 2021 | 886 | 0.170 |
Why?
| | Oxycodone | 1 | 2021 | 44 | 0.170 |
Why?
| | Dysbiosis | 1 | 2022 | 180 | 0.170 |
Why?
| | New Guinea | 2 | 2018 | 4 | 0.170 |
Why?
| | Surgery Department, Hospital | 1 | 2020 | 20 | 0.170 |
Why?
| | Knee Joint | 2 | 2021 | 406 | 0.170 |
Why?
| | Gastric Bypass | 1 | 2022 | 118 | 0.170 |
Why?
| | Arthroplasty | 1 | 2020 | 47 | 0.170 |
Why?
| | Terminal Care | 1 | 2023 | 224 | 0.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1683 | 0.170 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 46 | 0.160 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2022 | 236 | 0.160 |
Why?
| | Hypersensitivity | 1 | 2023 | 257 | 0.160 |
Why?
| | Faculty | 1 | 2021 | 144 | 0.160 |
Why?
| | Artemisinins | 1 | 2019 | 3 | 0.160 |
Why?
| | Intensive Care Units | 2 | 2022 | 802 | 0.160 |
Why?
| | Antimalarials | 1 | 2019 | 31 | 0.160 |
Why?
| | Phenotype | 2 | 2025 | 3199 | 0.160 |
Why?
| | Child | 12 | 2025 | 21968 | 0.160 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2019 | 143 | 0.160 |
Why?
| | Latent Tuberculosis | 1 | 2010 | 69 | 0.150 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 254 | 0.150 |
Why?
| | Prisons | 1 | 2010 | 80 | 0.150 |
Why?
| | Vaccination | 2 | 2025 | 1378 | 0.150 |
Why?
| | Waiting Lists | 2 | 2021 | 262 | 0.150 |
Why?
| | General Surgery | 1 | 2021 | 169 | 0.150 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 74 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 806 | 0.150 |
Why?
| | Laparoscopy | 1 | 2023 | 464 | 0.150 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 309 | 0.150 |
Why?
| | Healthcare Disparities | 3 | 2025 | 649 | 0.150 |
Why?
| | Rural Population | 2 | 2020 | 561 | 0.150 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 186 | 0.150 |
Why?
| | Aftercare | 1 | 2020 | 209 | 0.150 |
Why?
| | Organ Transplantation | 1 | 2021 | 247 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1568 | 0.150 |
Why?
| | Defibrillators, Implantable | 1 | 2022 | 315 | 0.150 |
Why?
| | Triage | 1 | 2021 | 220 | 0.150 |
Why?
| | Datasets as Topic | 1 | 2019 | 119 | 0.150 |
Why?
| | Social Marketing | 1 | 2008 | 14 | 0.150 |
Why?
| | Outpatients | 1 | 2022 | 393 | 0.150 |
Why?
| | Soft Tissue Infections | 1 | 2008 | 36 | 0.150 |
Why?
| | Hospitals, University | 1 | 2018 | 180 | 0.150 |
Why?
| | Cognition | 2 | 2023 | 1166 | 0.150 |
Why?
| | Ventricular Function | 1 | 2018 | 60 | 0.150 |
Why?
| | Developed Countries | 1 | 2018 | 39 | 0.150 |
Why?
| | Community Participation | 1 | 2019 | 130 | 0.140 |
Why?
| | Quinolines | 1 | 2019 | 177 | 0.140 |
Why?
| | Obesity, Morbid | 1 | 2022 | 258 | 0.140 |
Why?
| | Reproductive Medicine | 1 | 2008 | 15 | 0.140 |
Why?
| | Computers, Handheld | 1 | 2018 | 25 | 0.140 |
Why?
| | Autistic Disorder | 1 | 2020 | 201 | 0.140 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 167 | 0.140 |
Why?
| | Patient Admission | 1 | 2019 | 191 | 0.140 |
Why?
| | Burns | 1 | 2022 | 323 | 0.140 |
Why?
| | Climate | 1 | 2018 | 93 | 0.140 |
Why?
| | Population Groups | 1 | 2018 | 62 | 0.140 |
Why?
| | ROC Curve | 1 | 2019 | 545 | 0.140 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 442 | 0.140 |
Why?
| | Geography | 1 | 2018 | 197 | 0.140 |
Why?
| | Sentinel Surveillance | 1 | 2017 | 47 | 0.140 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2019 | 99 | 0.140 |
Why?
| | Condoms | 1 | 2008 | 104 | 0.140 |
Why?
| | Immunoglobulin A | 1 | 2019 | 210 | 0.140 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2023 | 115 | 0.140 |
Why?
| | Safety-net Providers | 1 | 2019 | 117 | 0.140 |
Why?
| | Recovery of Function | 1 | 2021 | 655 | 0.140 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 114 | 0.140 |
Why?
| | Patient Compliance | 1 | 2021 | 576 | 0.130 |
Why?
| | Occupational Health | 1 | 2010 | 200 | 0.130 |
Why?
| | Epidemics | 1 | 2018 | 87 | 0.130 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 350 | 0.130 |
Why?
| | Lymph Node Excision | 3 | 2023 | 170 | 0.130 |
Why?
| | Qualitative Research | 1 | 2024 | 1359 | 0.130 |
Why?
| | Gastroenteritis | 1 | 2017 | 68 | 0.130 |
Why?
| | Cell Phone | 1 | 2017 | 75 | 0.130 |
Why?
| | Anxiety Disorders | 1 | 2010 | 374 | 0.130 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 70 | 0.130 |
Why?
| | Students, Medical | 1 | 2021 | 341 | 0.130 |
Why?
| | Influenza Vaccines | 1 | 2021 | 539 | 0.130 |
Why?
| | Telemedicine | 1 | 2025 | 847 | 0.130 |
Why?
| | Parents | 1 | 2025 | 1355 | 0.130 |
Why?
| | Occupational Exposure | 1 | 2010 | 337 | 0.130 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 500 | 0.130 |
Why?
| | Fever | 1 | 2017 | 307 | 0.120 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 103 | 0.120 |
Why?
| | Patient Readmission | 2 | 2020 | 695 | 0.120 |
Why?
| | Forecasting | 1 | 2018 | 384 | 0.120 |
Why?
| | Alcoholism | 1 | 2023 | 804 | 0.120 |
Why?
| | Nurse Practitioners | 1 | 2018 | 135 | 0.120 |
Why?
| | Prospective Studies | 6 | 2025 | 7583 | 0.120 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5115 | 0.120 |
Why?
| | Morbidity | 3 | 2022 | 322 | 0.120 |
Why?
| | Models, Organizational | 1 | 2016 | 146 | 0.120 |
Why?
| | Melanoma | 1 | 2022 | 757 | 0.120 |
Why?
| | Humidity | 1 | 2015 | 50 | 0.120 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 390 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2022 | 852 | 0.120 |
Why?
| | Advance Care Planning | 1 | 2018 | 203 | 0.120 |
Why?
| | Mass Screening | 2 | 2020 | 1262 | 0.120 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 840 | 0.120 |
Why?
| | Mobile Applications | 1 | 2017 | 180 | 0.110 |
Why?
| | Antibodies, Viral | 1 | 2019 | 622 | 0.110 |
Why?
| | Diarrhea | 3 | 2023 | 183 | 0.110 |
Why?
| | Cannabidiol | 1 | 2016 | 119 | 0.110 |
Why?
| | Massage | 2 | 2010 | 43 | 0.110 |
Why?
| | Anticonvulsants | 1 | 2016 | 216 | 0.110 |
Why?
| | Emergency Medical Services | 1 | 2021 | 548 | 0.110 |
Why?
| | Stroke | 1 | 2023 | 1129 | 0.110 |
Why?
| | Time Factors | 5 | 2024 | 6792 | 0.110 |
Why?
| | Survival Rate | 3 | 2024 | 1969 | 0.110 |
Why?
| | Models, Biological | 1 | 2021 | 1769 | 0.110 |
Why?
| | Family Practice | 1 | 2018 | 455 | 0.110 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1942 | 0.110 |
Why?
| | Parasitemia | 1 | 2013 | 13 | 0.110 |
Why?
| | Chronic Pain | 1 | 2018 | 255 | 0.110 |
Why?
| | Indians, North American | 1 | 2009 | 625 | 0.100 |
Why?
| | Research | 1 | 2016 | 445 | 0.100 |
Why?
| | Environmental Exposure | 1 | 2018 | 576 | 0.100 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1045 | 0.100 |
Why?
| | Software | 1 | 2018 | 663 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2847 | 0.100 |
Why?
| | Medicaid | 1 | 2017 | 433 | 0.100 |
Why?
| | Epilepsy | 1 | 2016 | 332 | 0.100 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 552 | 0.100 |
Why?
| | Axilla | 2 | 2023 | 47 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1455 | 0.100 |
Why?
| | Diagnostic Tests, Routine | 2 | 2024 | 109 | 0.090 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 307 | 0.090 |
Why?
| | Emergencies | 2 | 2025 | 164 | 0.090 |
Why?
| | Temperature | 1 | 2015 | 674 | 0.090 |
Why?
| | Feedback | 2 | 2023 | 173 | 0.090 |
Why?
| | Washington | 2 | 2025 | 154 | 0.090 |
Why?
| | Patients | 2 | 2023 | 173 | 0.090 |
Why?
| | Pain Management | 2 | 2010 | 347 | 0.090 |
Why?
| | Prevalence | 3 | 2023 | 2712 | 0.090 |
Why?
| | Uganda | 2 | 2023 | 72 | 0.090 |
Why?
| | Age Factors | 4 | 2021 | 3290 | 0.090 |
Why?
| | Disease Progression | 1 | 2019 | 2750 | 0.090 |
Why?
| | Internship and Residency | 1 | 2021 | 1131 | 0.090 |
Why?
| | Lymphatic Metastasis | 2 | 2023 | 350 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2831 | 0.090 |
Why?
| | Heart Transplantation | 1 | 2017 | 747 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2491 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2129 | 0.080 |
Why?
| | Laboratories | 2 | 2021 | 113 | 0.080 |
Why?
| | Postoperative Period | 2 | 2021 | 343 | 0.080 |
Why?
| | Anti-HIV Agents | 1 | 2016 | 772 | 0.080 |
Why?
| | Guatemala | 2 | 2023 | 326 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2015 | 648 | 0.080 |
Why?
| | Societies, Medical | 2 | 2024 | 820 | 0.080 |
Why?
| | Lymph Nodes | 2 | 2023 | 492 | 0.080 |
Why?
| | Pandemics | 3 | 2023 | 1619 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 939 | 0.080 |
Why?
| | Anti-Bacterial Agents | 3 | 2025 | 1799 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2023 | 5749 | 0.070 |
Why?
| | Guideline Adherence | 2 | 2024 | 543 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2023 | 1260 | 0.070 |
Why?
| | Comorbidity | 2 | 2022 | 1611 | 0.070 |
Why?
| | Immunization Programs | 1 | 2009 | 213 | 0.070 |
Why?
| | Echocardiography | 2 | 2022 | 659 | 0.070 |
Why?
| | Referral and Consultation | 2 | 2023 | 777 | 0.060 |
Why?
| | Urban Population | 2 | 2020 | 472 | 0.060 |
Why?
| | School Health Services | 1 | 2009 | 239 | 0.060 |
Why?
| | Length of Stay | 2 | 2023 | 1208 | 0.060 |
Why?
| | Insurance Coverage | 2 | 2017 | 228 | 0.060 |
Why?
| | Affect | 1 | 2008 | 293 | 0.060 |
Why?
| | Nebraska | 1 | 2025 | 18 | 0.060 |
Why?
| | Wyoming | 1 | 2025 | 36 | 0.060 |
Why?
| | Pilot Projects | 2 | 2023 | 1697 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2022 | 6046 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5417 | 0.060 |
Why?
| | Acute Disease | 2 | 2017 | 1006 | 0.050 |
Why?
| | Cytokines | 2 | 2023 | 2088 | 0.050 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1281 | 0.050 |
Why?
| | Body Mass Index | 2 | 2023 | 2364 | 0.050 |
Why?
| | Animals | 4 | 2025 | 36768 | 0.050 |
Why?
| | Health Care Surveys | 2 | 2010 | 563 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2024 | 217 | 0.050 |
Why?
| | Motivational Interviewing | 1 | 2025 | 103 | 0.050 |
Why?
| | Herniorrhaphy | 1 | 2023 | 60 | 0.050 |
Why?
| | Community Health Workers | 1 | 2023 | 61 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 16 | 0.050 |
Why?
| | Health Facilities | 1 | 2023 | 83 | 0.050 |
Why?
| | Growth Disorders | 1 | 2023 | 86 | 0.050 |
Why?
| | Sternotomy | 1 | 2022 | 26 | 0.050 |
Why?
| | Death | 1 | 2023 | 118 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2022 | 21 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 34 | 0.050 |
Why?
| | Cardiology | 1 | 2025 | 278 | 0.050 |
Why?
| | Papua New Guinea | 1 | 2012 | 9 | 0.050 |
Why?
| | Vomiting | 1 | 2023 | 129 | 0.050 |
Why?
| | Breast | 1 | 2023 | 150 | 0.050 |
Why?
| | Burn Units | 1 | 2022 | 48 | 0.050 |
Why?
| | Alleles | 1 | 2025 | 888 | 0.050 |
Why?
| | Cough | 1 | 2023 | 121 | 0.050 |
Why?
| | Stroke Volume | 1 | 2025 | 619 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 47 | 0.050 |
Why?
| | HIV Infections | 1 | 2016 | 2812 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2023 | 209 | 0.050 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 107 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2023 | 687 | 0.050 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 55 | 0.050 |
Why?
| | Survival Analysis | 1 | 2024 | 1319 | 0.050 |
Why?
| | Demography | 1 | 2022 | 291 | 0.040 |
Why?
| | Sample Size | 1 | 2021 | 117 | 0.040 |
Why?
| | Neurosurgical Procedures | 1 | 2023 | 197 | 0.040 |
Why?
| | Gastrectomy | 1 | 2022 | 123 | 0.040 |
Why?
| | Educational Status | 1 | 2023 | 482 | 0.040 |
Why?
| | Preoperative Period | 1 | 2021 | 130 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2023 | 342 | 0.040 |
Why?
| | Habits | 1 | 2020 | 49 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 664 | 0.040 |
Why?
| | Research Personnel | 1 | 2022 | 170 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 226 | 0.040 |
Why?
| | Focus Groups | 1 | 2023 | 508 | 0.040 |
Why?
| | Censuses | 1 | 2020 | 31 | 0.040 |
Why?
| | Lung | 2 | 2024 | 4065 | 0.040 |
Why?
| | South Africa | 1 | 2021 | 219 | 0.040 |
Why?
| | Reoperation | 1 | 2023 | 565 | 0.040 |
Why?
| | Schools, Medical | 1 | 2021 | 146 | 0.040 |
Why?
| | Fear | 1 | 2023 | 338 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1235 | 0.040 |
Why?
| | Policy | 1 | 2021 | 148 | 0.040 |
Why?
| | Blood Proteins | 1 | 2022 | 249 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 495 | 0.040 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 46 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 243 | 0.040 |
Why?
| | Urination Disorders | 1 | 2019 | 13 | 0.040 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2019 | 10 | 0.040 |
Why?
| | Organoplatinum Compounds | 1 | 2019 | 46 | 0.040 |
Why?
| | Mentors | 1 | 2021 | 197 | 0.040 |
Why?
| | Risk | 1 | 2022 | 904 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2023 | 1373 | 0.040 |
Why?
| | Leucovorin | 1 | 2019 | 82 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 365 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 532 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 514 | 0.040 |
Why?
| | Kenya | 1 | 2019 | 115 | 0.040 |
Why?
| | Cardiovascular Nursing | 1 | 2018 | 3 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 400 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 487 | 0.040 |
Why?
| | Drug Combinations | 1 | 2019 | 344 | 0.040 |
Why?
| | Colombia | 1 | 2018 | 41 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 557 | 0.040 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2019 | 152 | 0.040 |
Why?
| | Fluorouracil | 1 | 2019 | 210 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 2009 | 249 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2010 | 276 | 0.040 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 390 | 0.040 |
Why?
| | Patient-Centered Care | 1 | 2023 | 520 | 0.040 |
Why?
| | Chronic Disease | 1 | 2024 | 1784 | 0.040 |
Why?
| | Biomedical Research | 1 | 2024 | 689 | 0.030 |
Why?
| | Rectum | 1 | 2019 | 185 | 0.030 |
Why?
| | Coinfection | 1 | 2019 | 136 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1274 | 0.030 |
Why?
| | Odds Ratio | 1 | 2010 | 1063 | 0.030 |
Why?
| | Mortality | 1 | 2019 | 357 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2021 | 572 | 0.030 |
Why?
| | Viral Load | 1 | 2019 | 460 | 0.030 |
Why?
| | Proctitis | 1 | 2016 | 6 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 807 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1055 | 0.030 |
Why?
| | Urogenital System | 1 | 2016 | 17 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 775 | 0.030 |
Why?
| | Mental Health | 1 | 2023 | 721 | 0.030 |
Why?
| | Latin America | 1 | 2016 | 92 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 324 | 0.030 |
Why?
| | Sexually Transmitted Diseases | 1 | 2008 | 158 | 0.030 |
Why?
| | Prisoners | 1 | 2008 | 143 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 470 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2017 | 129 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 267 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1032 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 781 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2016 | 145 | 0.030 |
Why?
| | Self Care | 1 | 2018 | 375 | 0.030 |
Why?
| | Plant Extracts | 1 | 2016 | 200 | 0.030 |
Why?
| | Electrocardiography | 1 | 2018 | 628 | 0.030 |
Why?
| | Insurance, Health | 1 | 2017 | 278 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 979 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 576 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 845 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 891 | 0.030 |
Why?
| | Hemorrhage | 1 | 2019 | 723 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 808 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1714 | 0.030 |
Why?
| | Mutation | 1 | 2025 | 3953 | 0.030 |
Why?
| | Neoplasms | 1 | 2008 | 2644 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3272 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3537 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2068 | 0.020 |
Why?
| | Health Promotion | 1 | 2008 | 736 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2834 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 4158 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2015 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 2975 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2008 | 286 | 0.020 |
Why?
| | Veterans | 1 | 2009 | 1457 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2009 | 976 | 0.010 |
Why?
|
|
Colborn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|